JPMorgan Chase & Co. Has Lowered Expectations for Tempus AI (NASDAQ:TEM) Stock Price

Tempus AI (NASDAQ:TEM) had its price objective dropped by investment analysts at JPMorgan Chase & Co. from $80.00 to $60.00 in a research report issued on Wednesday,Benzinga reports. The firm presently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price objective would indicate a potential upside of 8.28% from the stock’s current price.

A number of other research analysts also recently commented on TEM. Morgan Stanley boosted their price objective on shares of Tempus AI from $80.00 to $85.00 and gave the company an “overweight” rating in a research report on Monday, December 1st. BTIG Research lowered their price target on shares of Tempus AI from $105.00 to $90.00 and set a “buy” rating on the stock in a report on Wednesday. HC Wainwright cut their price objective on Tempus AI from $98.00 to $89.00 and set a “buy” rating for the company in a report on Friday, November 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Tempus AI in a research report on Thursday, January 22nd. Finally, Canaccord Genuity Group dropped their target price on Tempus AI from $95.00 to $80.00 and set a “buy” rating on the stock in a research report on Monday, December 22nd. Eight research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $79.31.

Tempus AI Trading Up 3.2%

NASDAQ:TEM opened at $55.41 on Wednesday. The stock has a market cap of $9.86 billion, a PE ratio of -39.30 and a beta of 5.22. Tempus AI has a fifty-two week low of $36.22 and a fifty-two week high of $104.32. The company has a debt-to-equity ratio of 2.52, a current ratio of 3.13 and a quick ratio of 3.12. The stock’s 50-day moving average is $61.57 and its two-hundred day moving average is $73.33.

Insider Activity at Tempus AI

In other news, EVP Erik Phelps sold 9,464 shares of Tempus AI stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $59.43, for a total value of $562,445.52. Following the transaction, the executive vice president owned 79,816 shares of the company’s stock, valued at $4,743,464.88. This trade represents a 10.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Eric P. Lefkofsky sold 166,250 shares of the business’s stock in a transaction on Wednesday, January 28th. The stock was sold at an average price of $65.56, for a total transaction of $10,899,350.00. Following the completion of the sale, the chief executive officer owned 8,941,533 shares of the company’s stock, valued at $586,206,903.48. The trade was a 1.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 596,035 shares of company stock valued at $37,505,125. 26.27% of the stock is owned by company insiders.

Institutional Trading of Tempus AI

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its stake in Tempus AI by 8.7% during the fourth quarter. Vanguard Group Inc. now owns 10,258,621 shares of the company’s stock worth $605,772,000 after purchasing an additional 817,014 shares during the period. ARK Investment Management LLC increased its position in Tempus AI by 5.3% in the 4th quarter. ARK Investment Management LLC now owns 7,557,583 shares of the company’s stock valued at $446,275,000 after acquiring an additional 381,816 shares in the last quarter. GC Wealth Management RIA LLC bought a new stake in shares of Tempus AI during the fourth quarter valued at approximately $399,267,000. Sumitomo Mitsui Trust Group Inc. raised its position in Tempus AI by 1.2% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,504,823 shares of the company’s stock worth $206,960,000 after purchasing an additional 41,728 shares during the last quarter. Finally, Amova Asset Management Americas Inc. raised its position in Tempus AI by 1.2% in the 4th quarter. Amova Asset Management Americas Inc. now owns 3,504,823 shares of the company’s stock worth $206,960,000 after purchasing an additional 41,728 shares during the last quarter. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Q4 beat with strong top-line growth and raised 2026 revenue guidance — Tempus reported robust revenue growth (driven by diagnostics, MRD and Data & Applications), narrowed losses and issued a 2026 revenue target of about $1.59B, supporting the company’s growth-and-path-to-profit narrative. Tempus AI Sold Off After a Beat—But the Rebound Case Is Building
• Positive Sentiment: New AI tools and a strategic partnership broaden addressable market — Tempus launched an HRD‑RNA AI algorithm for oncology and partnered with Median Technologies to integrate advanced lung‑cancer screening tools, strengthening its diagnostic pipeline and platform differentiation. Tempus AI Deepens Precision Oncology Role With New HRD And Lung Tools
• Neutral Sentiment: CEO to speak at Morgan Stanley TMT conference — Eric Lefkofsky will appear March 3; the presentation is a near-term opportunity to clarify guidance, margin cadence and commercialization progress. Tempus to Participate in the Morgan Stanley Technology, Media & Telecom Conference
• Neutral Sentiment: Analyst coverage and comparisons continue to shape expectations — industry writeups (e.g., TEM vs. ILMN) emphasize the balance between near‑term execution and long‑term transformation in medtech/AI healthcare, making investor focus on execution more acute. TEM vs. ILMN: Which MedTech Stock Offers Greater Upside?
• Negative Sentiment: Multiple price‑target cuts this week pressured sentiment — JPMorgan cut its target to $60 (neutral), Needham lowered to $75 (buy), and BTIG trimmed to $90 — that combination tightened near-term upside expectations despite mixed analyst ratings. JPMorgan price target cut Needham price target lowered BTIG price target cut
• Negative Sentiment: After‑hours reaction driven by wider loss and profitability concerns — despite revenue outperformance, EPS missed and some commentary left investors unsure about near‑term margin/scale progress, prompting a pullback in the session following the print. TEM Q4 Earnings Miss, Revenues Beat, Stock Down in After-Market

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.